Indian Solution to Global Health Problems due to unmet medical needs & prevention of Pandemic 2.0

Problem
Global Health Problems due to unmet medical needs viz Cancer, Immunity & Neural disorders and pandemics Long COVID-19, Bird Flu, Swine Flu, Drug resistant AIDS/TB, Super bug & chronic immunity disorders.

People with weak immunity are at higher risk of getting these infections with increased morbidity.

Solution
Receptol, with 108 global unmet medical need therapeutic Product & Process granted Patents in US, UK, across EU, Africa & India, Nano informational peptides that cross Blood Brain Barrier from mother's 1st milk /bovine colostrum acts at Pituitary gland in Brain sending neural signals to augment the immune system by 5X macrophage production from Thymus and increase in Tumour necrosis factors, interleukin 1-11 and interferon Alpha and Gamma from the bone marrow B cells that also helps immune modulation and closing the entry points on the receptor of cell surface that are used by foreign agents like virus, bacteria, and fungus. Enter the body along with checkpoint blocking for the cancer stem cells.

Innovation Journey –
After 18 years of R&D, and 15 years of follow up with Full blown totally immunocompromised AIDS and Swine Flu patients as a model with opportunistic infections and sarcoma fully treated and cured with no recurrence during 15 years long follow-up studies that is being published in New England Journal of Medicine, Nature & Science based on global studies with nano peptides successfully isolated from all mammalian colostrum.

Product - RECEPTOL®, made from bovine Colostrum Nano-peptides helps people lead longer & healthier lives by building the body's immune system, thus aiding in prevention and cure for communicable & unmet Immunity diseases using an accelerated, prospective Phase III global efficacy and safety studies for Receptol Monotherapy was conducted for using full blown AIDS patients with associated Immunity & associated 18 clinical symptoms including Kaposi Sarcoma with long term follow up showed significant resolution of all symptoms within 3 weeks.

Active Ingredients (API) - Active Pharmaceutical Ingredients consist of proline, rich polypeptides & Patented Nano-Informational Peptides Radha108 eight Mer amino acid sequences extracted from mammalian/ bovine colostrum using World's 1st Ultra Nano filtration Technology on commercial level, having no side effects and can be taken safely by all age groups from infants' friends to old patients.

Mode of Action -
Receptol® nano informational peptides gets absorbed in the blood through the buccal mucosa and crosses the Blood-Brain-Barrier. It stimulates maturation of immature thymocytes into either helper or suppressor T cells. It stimulates secretion of Tumour Necrosis Factor & cytokines IL-1 to IL-11, INF-a, INF-y. Activates Natural Killer (NK) Cells, cytotoxic cells of the innate immune system by 5 times.

RECEPTOL® exposes the patient's immune system to the memory of a health threat, whether foreign or native, and the knowledge of how to best respond to protect itself via building body's own immune system naturally like a new born baby is protected with mother's 1st 3 lactation having colostrum milk.

Government recognition:

Health Minister of India released a Book on RECEPTOL- The Next Wonder Drug, creating a Paradigm shift from prevention to treatment providing health for All.

Federal Ministry of Science & Technology & Health of Govt of India organised monitored & funded the Global and Indian Studies including FDA approvals.

USP- Innovative with common Mode of Action for 108 unmet medical needs, affordable, Globally Patented, broad spectrum, easy to administer,
100% Efficacy with no side effects, can be consumed by all age groups and has no age or sex barriers.

Mammalian colostrum derived nano peptides for broad-spectrum viral and recurrent infections with a method of isolation thereof

Global Granted Therapeutic Product & Process Patents for unmet medical needs: 58 indications in the United States of America, and 108 indications across the European Union, United Kingdom, Africa, and India

1) United States - Date of issue - 02-02-2016, Extension Date - 14-03-2030
Link to the PTO website – Application Number – 13845577
https://biomix.in/images/pdf/us9249188.pdf
Global Patents Link - https://patents.google.com/patent/US20130274177A1/en?oq=13845577

Claim – 1 - The method of claim 1, wherein the immune related disorders are selected from the group consisting of autism mane disorders, allergies, Alzheimer's, Benign Prostatic Hyperplasia, Cancer, Hypertension, Lupus. Thrush, Autism, Perthes disease, Premenstrual syndrome and Endometriosis, Prion disease, Psoriasis, Sjogren's Syndrome, Spinal Musca lar Atrophy, Thrombocytopenia, burns, infection, insect bites, diaper rash, herpetic lesions, Pharyngitis, Porphyria, Raynaud's phenomenon, Sarcoidosis, Celiac disease, Chronic Pancytopenia, Crohn's disease, Diabetes type II, Fibromyalgia Rheumatica, Mononucleosis, Multiple Sclera sis, Rheumatoid Arthritis, Osteo Arthritis, Spinal Muscular Atrophy, Brown Recluse Spider Bite, Corneal Regeneration, diarrhoea, Guillain Barre Syndrome, Haemolytic Anaemia, Idiom pathic thrombocytopenic purpura, Myasthenia Gravis, tuber colossi, Human Immunodeficiency Virus (HIV), Hepatitis A and C. Rabies in Dogs, Acute Viral Infections, Dengue fever, Human Papilloma Virus, Parvo, Rabies, Severe Acute Res purgatory Syndrome (SARS), Shingles, Viral Respiratory Infection, Planta

2) United States - Date of Issue – 27-08-2013, Extension Date - 29-12-2029

Link to the PTO website - Application Number - 13/142327
https://biomix.in/images/grant-certificate-us.pdf

Global Patents Link - https://patents.google.com/patent/US20110319321A1/en?oq=13%2f142327

Claim – 18 - A method for the treatment of Acquired Immune Deficiency Syndrome (AIDS), the method comprising administering to a patient suffering from such disorder a therapeutically effective amount of the formulation comprising peptides of SEQ ID 1-8 as claimed in claim 1.

3) South Africa - Date of Issue – 19-02-2012, Extension Date - 24-06-2031

Link to the PTO website - Application Number - 2011/04687
https://biomix.in/images/granted-certificate-south-africa.pdf

4) Great Britain - Date of Issue – 29-12-2009, Extension Date - 29-12-2029
Link to the PTO website - Application Number - MU13532008
https://biomix.in/images/pdf/great-britain-patent-certificate.pdf

5) Romania - Date of Issue – 29-12-2009, Extension Date - 29-12-2029

Link to the PTO website - Application Number - EP09827010A
https://biomix.in/images/pdf/romania-patent-certificate.pdf

6) Canada - Date of Issue – 29-12-2009, Extension Date - 29-12-2029
Link to the PTO website - Application Number – CA2748449A
https://biomix.in/images/pdf/canada-patent-certificate.pdf

7) Austria - Date of Issue – 29-12-2009, Extension Date - 29-12-2029

Link to the PTO website - Application Number – 2009827010
https://biomix.in/images/pdf/austria-patent-details.pdf

8) Italy - Date of Issue – 29-12-2009, Extension Date - 29-12-2029

Link to the PTO website - Application Number – 502016000118902
https://biomix.in/images/pdf/italy-patent-certificate.pdf

9) Germany - Date of Issue – 20-02-2017, Extension Date - 29-12-2029

Link to the PTO website - Application Number – WO2010079511A2
https://biomix.in/images/pdf/germany-patent-certificate.pdf

10) Spain - Date of Issue – 29-12-2009, Extension Date - 29-12-2029

Link to the PTO website - Application Number – 09827010.1
Not found

11) Ireland - Date of Issue – 29-12-2009, Extension Date - 29-12-2029

Link to the PTO website - Application Number – EP09827010A
https://biomix.in/images/pdf/ireland-patent-certificate.pdf

12) Netherlands - Date of Issue – 29-12-2009, Extension Date - 29-12-2029

Link to the PTO website - Application Number – EP09827010.1
https://biomix.in/images/pdf/netherland-patent-certificate.pdf

13) Belgium - Date of Issue – 29-12-2009, Extension Date - 29-12-2029

Link to the PTO website - Application Number – 098270101
https://biomix.in/images/pdf/belgium-patent-certificate.pdf

14) Sweden - Date of Issue – 29-12-2009, Extension Date - 29-12-2029

Link to the PTO website - Application Number – EP 09827010.1
https://biomix.in/images/pdf/sweden-patent-certificate.pdf

15) India - Date of Issue – 19-02-2025, Extension Date - 27-12-2028

Link to the PTO website - Application Number – 1353/MUM/2008
https://biomix.in/images/pdf/Indian-Patent-certificate.pdf

Pls note per attached our Immunity Drug RECEPTOL Patent status in the United States, UK, Europe, Africa, Asia Pacific active and have at least 10 years plus duration in most countries with 108 disease indications approved by the patent authorities across Europe, UK, Africa & Asia PAC and 58 disease prevention & treatment in the United States of America including that of all communicable and viral infections, cancer, diabetes, weight loss, and neural disorders, like Alzheimer's Parkinson.

Indian patient for 108 unmet medical need issued in February 2025, is likely to be extended by Mumbai High Court up to 2045.